Primary esophageal non-Hodgkin ’s lymphoma: demographics, clinical characteristics, histopathologic types, and survival in 179 patients from the SEER program and systematic review of the literature
ConclusionsIn this large population-based series, diagnosis after 1997 (year of rituximab approval by the FDA) and MZL subtype were associated with improved survival outcomes in patients with PEL.
Source: Esophagus - Category: Gastroenterology Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Epidemiology | Esophagus Cancer | Gastroenterology | Hodgkin's Disease | Lymphoma | Rituxan | Study